Raymond Cha, Sarah M. Michienzi and Lama Hsaiky
While infections due to multidrug-resistant Gram-negative organisms overwhelm hospitals worldwide, preservation of current antimicrobial treatment options becomes paramount in the face of dwindling development of novel antibiotics. There is extensive data demonstrating that application of pharmacokinetic/pharmacodynamic principles improves the possibility of enhancing clinical and microbiological outcome. There is expanding evidence demonstrating that unfavorable clinical outcomes and antimicrobial resistance may be suppressed when specific pharmacokinetic/pharmacodynamic targets are attained for beta-lactam and carbapenem antibiotics. This paper highlights pertinent studies that contribute to the principles and application of these principles.